EA
NVS icon

Euclid Advisors’s Novartis NVS Stock Holding History

Euclid Advisors’s Portfolio NVS Stock Details NVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-79,216
Closed -$6.53M – 476
2015
Q3 		$6.53M Buy
79,216
+5,240
+7% +$466K 0.3% 113
2015
Q2 		$6.52M Buy
73,976
+29,024
+65% +$2.66M 0.13% 210
2015
Q1 		$3.97M Sell
44,952
-525
-1% -$46.6K 0.07% 226
2014
Q4 		$3.78M Buy
45,477
+1,172
+3% +$97.1K 0.04% 319
2014
Q3 		$3.74M Buy
+44,305
New +$3.58M 0.03% 423

Other funds holding NVS

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BBHC
Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
IC
Institutional Capital Chicago, Illinois $6.75B AUM 3.44% 1-Year Est. Return

Euclid Advisors's NVS Position: Q4 2015 in Review

Euclid Advisors sold out of Novartis (NVS) in Q4 2015, closing a stake of 79,216 shares — an estimated $6.53M sold.

Euclid Advisors first reported a position in NVS in Q3 2014 and held it in 5 quarters. The position peaked at $6.53M in Q3 2015. 926 funds tracked by Wall St. Rank hold NVS as of Q4 2015.

  • Euclid Advisors reported no remaining Novartis position as of Q4 2015 after selling out during the quarter.
  • Euclid Advisors sold 79,216 Novartis shares in Q4 2015, an estimated $6.53M.
  • Euclid Advisors first reported a position in Novartis in Q3 2014 and held it in 5 quarters.
  • Euclid Advisors's Novartis position peaked at $6.53M in Q3 2015.
  • 926 funds tracked by Wall St. Rank held Novartis as of Q4 2015.

Based on Euclid Advisors's 13F filing for Q4 2015, filed 16 Feb 2016.